{'fraction_non_alphanumeric': 0.032989690721649485, 'fraction_numerical': 0.0, 'mean_word_length': 5.845070422535211, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Mapping the MET Receptor Tyrosine Kinase Interactome using Mammalian Membrane Two Hybrid (MaMTH) system

MET receptor tyrosine kinase is a growth factor receptor implicated in majority of cancers including lung, breast, pancreas, ovary and brain. When aberrantly activated, MET exacerbates malignancies by promoting metastasis, anti‐apoptosis and a major hindrance to today’s anti‐cancer therapeutics ‐ cancer drug resistance. Thus, MET is a sought‐out target in cancer drug discovery.